BioControl (2013) 58, 715-722
of interest to a wider audience. We would welcome
contributions to the Discussion section (above tab) of this article.
Remember to log in or register (top right corner) before editing pages.
Progress in the commercialisation of bionematicides
BioControl 58 (6), 715-722
Abstract: In the last few years, there have been numerous developments in the commercialisation of bionematicides. Here we briefly review the commercial status of four key active ingredients backed by large international companies and which are, or are likely to become widely available soon. We also identify research priorities. While scientists have intensively researched Pasteuria spp. and Purpureocillium lilacinus as potential nematicides, little research has been done on Bacillus firmus and Myrothecium verrucaria fermentation products. Conversely, a survey of the trade press suggests that these latter two agents, particularly B. firmus, are the most widely used. There is a clear need to further understand the ecology and mode of action of B. firmus when used as a bionematicide. Furthermore, while all active ingredients have proven efficacy in laboratory and/or small plot trials, there is a paucity of independent data showing product efficacy in target markets.
(The abstract is excluded from the Creative Commons licence and has been copied with permission by the publisher.)
Link to article at publishers website
Database assignments for author(s): Michael J. Wilson
Research topic(s) for pests/diseases/weeds:
biocontrol - natural enemies
Research topic(s) for beneficials or antagonists:
Pest and/or beneficial records:
|Albifimbria verrucaria (antagonist)|
|Purpureocillium lilacinum (pathogen of nematodes)|
|Bacillus firmus (antagonist)|
|Pasteuria usgae (antagonist)|